Raloxifene shown safe for 8 years

Article

A study extending experience with raloxifene to 8 years shows no adverse impact on gynecologic health with longer-term use. Results of the Continuing Outcomes Relevant to EVISTA (CORE) trial build on and support previous findings from the 4-year Multiple Outcomes of Raloxifene Evaluation (MORE) trial.

A study extending experience with raloxifene to 8 years shows no adverse impact on gynecologic health with longer-term use. Results of the Continuing Outcomes Relevant to EVISTA (CORE) trial build on and support previous findings from the 4-year Multiple Outcomes of Raloxifene Evaluation (MORE) trial.

Presented at the 15th Annual Meeting of the North American Menopause Society, the CORE trial involved a subset of approximately 4,000 women who participated in MORE. MORE assessed raloxifene's efficacy in reducing breast cancer incidence over a 4-year period. CORE, in contrast, looked at the drug's impact on rates of endometrial cancer and hyperplasia and vaginal bleeding during the same period and for 4 years beyond.

Over the 8-year period, the placebo and raloxifene groups did not differ in incidence of uterine cancer, endometrial hyperplasia, ovarian cancer, or vaginal bleeding. There were also similar rates of self-reported pelvic organ prolapse in the two groups. Overall, there were 11 uterine cancers, 11 cases of endometrial hyperplasia, five ovarian cancers, and 41 cases of vaginal bleeding reported.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Zachary Wagner, PhD, discusses the harms of bias in reproductive care | Image Credit: ornsife.usc.edu.
Ciera Kirkpatrick, PhD, shows how TikTok is transforming cervical cancer awareness | Image Credit: linkedin.com.
Maria Gallo, PhD, discusses high attendance at crisis pregnancy centers | Image Credit: © x.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.